title: Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression.
abstract: Lymphoproliferative disease developed in 15 heart and five lung transplant recipients during a decade of heart and lung transplantation from 1980 through 1989. The overall incidence of posttransplant lymphoproliferative disease in patients who survived more than 30 days is 4%. The incidence after heart transplantation is 3.4% and after lung transplantation is 7.9% (p = 0.08). The peak occurrence of posttransplant lymphoproliferative disease is 3 to 4 months after transplantation. However, posttransplant lymphoproliferative disease occurring early versus late (defined as before or after 1 year after transplantation) appears to have different clinical outcomes. The mortality of early onset of posttransplant lymphoproliferative disease as a result of lymphoma is 36%; response to reduction in immunotherapy occurs in 89% and presentation with disseminated disease occurs in 23%. The mortality of late onset of posttransplant lymphoproliferative disease as a result of lymphoma is 70%; no patient responded to reduction in immunotherapy and presentation with disseminated disease occurs in 86% of patients. Epstein-Barr virus primary infection was present in 14 and secondary Epstein-Barr virus infection was present in three of the 20 patients with posttransplant lymphoproliferative disease. The other three patients were positive for Epstein-Barr virus also but had no pretransplant sera for comparison. There is no correlation with immunoprophylaxis or maintenance immunosuppression and the development of posttransplant lymphoproliferative disease in our series.
authors.affiliation: Department of Surgery, University of Pittsburgh School of Medicine, Pa.
authors.forename: J M
authors.initials: JM
authors.lastname: Armitage
authors.forename: R L
authors.initials: RL
authors.lastname: Kormos
authors.forename: R S
authors.initials: RS
authors.lastname: Stuart
authors.forename: F J
authors.initials: FJ
authors.lastname: Fricker
authors.forename: B P
authors.initials: BP
authors.lastname: Griffith
authors.forename: M
authors.initials: M
authors.lastname: Nalesnik
authors.forename: R L
authors.initials: RL
authors.lastname: Hardesty
authors.forename: J S
authors.initials: JS
authors.lastname: Dummer
mesh_terms: D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D016027:Heart Transplantation; D016041:Heart-Lung Transplantation; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D015994:Incidence; D016040:Lung Transplantation; D016393:Lymphoma, B-Cell / Q000401:mortality*; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014412:Tumor Virus Infections / Q000401:mortality*
chemical_list: D016572:Cyclosporine